Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$0.58
-1.7%
$0.38
$0.17
$3.54
$1.85MN/A174,355 shs1,231 shs
ContraFect Co. stock logo
CFRX
ContraFect
$0.05
$0.05
$0.04
$13.02
$535K0.291.39 million shs910,216 shs
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
$0.02
-6.2%
$0.03
$0.02
$0.08
$1.71M1.9190,335 shs33,850 shs
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
$3.50
+2.0%
$3.73
$2.51
$2,064.00
$1.97M1.43266,154 shs17,325 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
0.00%+13.46%+31.08%+182.57%-79.24%
ContraFect Co. stock logo
CFRX
ContraFect
0.00%0.00%0.00%0.00%0.00%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
+7.11%+9.55%-2.43%-0.82%-63.37%
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
-0.43%-2.25%-7.32%-25.48%-99.82%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
1.6752 of 5 stars
0.03.00.04.60.60.01.9
ContraFect Co. stock logo
CFRX
ContraFect
N/AN/AN/AN/AN/AN/AN/AN/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
0.00
N/AN/AN/A
ContraFect Co. stock logo
CFRX
ContraFect
0.00
N/AN/AN/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
0.00
N/AN/AN/A
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/A$1.92 per shareN/A
ContraFect Co. stock logo
CFRX
ContraFect
N/AN/AN/AN/A($19.92) per shareN/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/A($2.41) per shareN/A
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
$19.29M0.10N/AN/A$163.50 per share0.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-$10.38M-$0.950.03N/AN/A-471.57%-296.50%N/A
ContraFect Co. stock logo
CFRX
ContraFect
-$65.15M-$19.27N/AN/AN/AN/AN/A-138.70%N/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
-$59.08M-$0.19N/AN/AN/AN/A-99.34%N/A
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
-$6.16MN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/AN/A
ContraFect Co. stock logo
CFRX
ContraFect
N/AN/AN/AN/AN/A
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/AN/AN/AN/AN/A
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/A
2.70
2.70
ContraFect Co. stock logo
CFRX
ContraFect
N/A
0.53
0.53
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
N/A
9.74
9.74
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
17.34%
ContraFect Co. stock logo
CFRX
ContraFect
7.85%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
50.77%
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
0.18%

Insider Ownership

CompanyInsider Ownership
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
1.80%
ContraFect Co. stock logo
CFRX
ContraFect
0.62%
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
12.90%
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
57.38%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
43.18 million2.02 millionNot Optionable
ContraFect Co. stock logo
CFRX
ContraFect
2310.70 million10.64 millionNot Optionable
Galera Therapeutics, Inc. stock logo
GRTX
Galera Therapeutics
3075.46 million47.38 millionOptionable
Universe Pharmaceuticals INC stock logo
UPC
Universe Pharmaceuticals
220563,000731,000Not Optionable

Recent News About These Companies

UPC’s Unexpected Plunge: What’s Next?
Universe Pharmaceuticals gets Nasdaq delisting notice
Avenue Therapeutics stock logo

Avenue Therapeutics NASDAQ:ATXI

$0.58 -0.01 (-1.69%)
As of 03:16 PM Eastern

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

ContraFect stock logo

ContraFect NASDAQ:CFRX

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

Galera Therapeutics stock logo

Galera Therapeutics NASDAQ:GRTX

$0.02 0.00 (-6.22%)
As of 03:34 PM Eastern

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

Universe Pharmaceuticals stock logo

Universe Pharmaceuticals NYSE:UPC

$3.50 +0.07 (+2.04%)
Closing price 03:57 PM Eastern
Extended Trading
$3.58 +0.08 (+2.40%)
As of 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is based in Ji'An, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.